Longboard Pharmaceuticals (LBPH) announced that the U.S. Food and Drug Administration has granted orphan drug designation to bexicaserin in the treatment of Lennox-Gastaut Syndrome.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals Inc options imply 0.8% move in share price post-earnings
- Largest borrow rate increases among liquid names
- Longboard Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
- Longboard Pharmaceuticals downgraded to Neutral from Buy at B. Riley
- Lundbeck Acquires Longboard Pharmaceuticals for $2.6 Billion